2024
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
1980
An Experimental Model to Determine the Effects of Adjuvant Therapy on the Incidence of Postoperative Wound Infection
Ariyan S, Kraft R, Goldberg N, Lawrie H. An Experimental Model to Determine the Effects of Adjuvant Therapy on the Incidence of Postoperative Wound Infection. Plastic & Reconstructive Surgery 1980, 65: 338-345. PMID: 6766559, DOI: 10.1097/00006534-198003000-00010.Peer-Reviewed Original ResearchConceptsWound infectionPostoperative wound infectionUse of methotrexateNormal wound healingLeucovorin treatmentPreoperative adjuvantAdjuvant therapyAdjuvant treatmentNeck cancerSurgical removalSurgical woundsRadiation therapyLD50 doseLarge dosesExperimental modelWound healingTherapyInfectionReasonable approachBacterial contaminationTreatmentOptimal timeMethotrexateAdjuvantMTX